ZBTB7A and acute myeloid leukemia: In the present study, we show that ZBTB7A can counteract RUNX1-RUNX1T1-dependent progenitor cell expansion through repression of glycolysis, opening up avenues for a targeted treatment of AML t(8;21) with metabolic inhibitors.